Feasibility of a collaborative palliative and oncology care intervention to improve symptoms and coping during head and neck chemoradiation.

Authors

null

Jessica Ruth Bauman

Fox Chase Cancer Center, Philadelphia, PA

Jessica Ruth Bauman, Jessie Panick, Thomas James Galloway, John A. Ridge, Melissa McShane, Marcin Chwistek, Molly Collins, Leigh Kinczewski, Kathleen Murphy, Marie Welsh, Matthew Farren, Mollie Clark, Jacqueline Kelly, Katherine Schuster, Lauren Stokes, Sheila Amrhein, Florence Bender, Brian L. Egleston, Areej El-Jawahri, Carolyn Y Fang

Organizations

Fox Chase Cancer Center, Philadelphia, PA, Fox Chase Cancer Center, Massachusetts General Hospital, Boston, MA

Research Funding

Other Foundation
Palliative Care Research Cooperative Group
Background: Patients receiving curative chemoradiation treatment (CRT) for head and neck cancer (HNC) undergo one of the most intensive treatments in oncology, resulting in immense physical and psychological symptoms. Integrated palliative care can improve symptoms and coping in patients with advanced cancer, but has not been evaluated in patients with curable solid tumors. Thus, we are conducting the first pilot study of a collaborative palliative and oncology care intervention among patients receiving CRT to assess feasibility and acceptability. Methods: Eligible participants include newly diagnosed HNC patients starting curative-intent CRT. The intervention entails weekly in-person palliative care (PC) visits integrated with standard oncology care during CRT, followed by 4 weekly phone calls after CRT ends. The PC visits are conducted primarily by a PC RN, with a supervising MD or NP available. Visits focus on coping and managing prominent symptoms during CRT. PC clinicians also receive a weekly patient-reported symptom assessment. Acceptability of the intervention is assessed at 1 month post CRT. The primary outcome is feasibility, defined as a >50% enrollment rate with >70% of participants attending at least half of the PC visits. Planned accrual is 20 patients. Results: We have enrolled 88% (14/16) of eligible patients to date. 11/14 (79%) have p16+ disease. All 14 have completed CRT and are evaluable for feasibility. Participants attended 98% (94/96) of all possible PC visits and completed 99% (95/96) of weekly symptom assessments. PC clinicians spent an average of 35.5 minutes (SD 15.1) per visit with participants. Among the 10 participants who completed the intervention and are evaluable for acceptability, 100% found the intervention “very helpful” and would “definitely recommend” it to others undergoing CRT. Conclusions: An integrated PC intervention to improve symptoms and coping during CRT for HNC is both feasible and acceptable with a high enrollment rate, excellent intervention compliance, and high patient satisfaction. Future studies will evaluate the effects of the integrated intervention on patient-reported outcomes and health care utilization.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Advance Care Planning,End-of-Life Care,Communication and Shared Decision Making,Integration and Delivery of Palliative and Supportive Care,Coordination and Continuity of Care,Caregiver Support,Biology of Symptoms and Treatment Toxicities,Disparities in Supportive Care

Sub Track

Integration and Delivery of Palliative and Supportive Care

Clinical Trial Registration Number

NCT03760471

Citation

J Clin Oncol 37, 2019 (suppl 31; abstr 73)

DOI

10.1200/JCO.2019.37.31_suppl.73

Abstract #

73

Poster Bd #

G4

Abstract Disclosures

Similar Abstracts

First Author: Farsha Rizwan

Abstract

2023 ASCO Quality Care Symposium

Receipt of only palliative care among patients with advanced-stage head and neck cancer.

First Author: Dina K Abouelella

Abstract

2023 ASCO Annual Meeting

Chronotherapy in head and neck cancer (HNC): A systematic review.

First Author: Abdel-Azez Abu-Samak